Céline Lepère

Université Paris Cité — France

Medicine · Health Sciences

21h-index2.8kcitations95works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(40), Neuroendocrine Tumor Research Advances(23), Pancreatic and Hepatic Oncology Research(20), Gastric Cancer Management and Outcomes(18), Cancer Genomics and Diagnostics(18)

Publications95 total

885eP Efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) as intensification or salvage treatment in metastatic colorectal cancer (mCRC): A retrospective analysis from an expert center
Annals of Oncology·2025
2811P Composite risk score for oncology patients receiving oral therapies in nurse-led follow-up
Annals of Oncology·2025
Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study
JNCI Journal of the National Cancer Institute·2025
Cardiac metastasis of colorectal cancer: a case report and review of literature
Clinics and Research in Hepatology and Gastroenterology·2025
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study
The Oncologist·2025Open Access
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials
Journal of Clinical Oncology·2025· 15 citedOpen Access
7MO Combined analyses of ctDNA and Immunoscore in stage III colon cancer patients: A post hoc analysis of the IDEA-France and -Greece trials
Annals of Oncology·2024Open Access
Data from Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a <i>Post Hoc</i> Analysis of the PRODIGE-GERCOR IDEA-France Trial
2023Open Access
Supplementary Data from Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a <i>Post Hoc</i> Analysis of the PRODIGE-GERCOR IDEA-France Trial
2023Open Access
Supplementary Data from Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a <i>Post Hoc</i> Analysis of the PRODIGE-GERCOR IDEA-France Trial
2023Open Access
Data from Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a <i>Post Hoc</i> Analysis of the PRODIGE-GERCOR IDEA-France Trial
2023Open Access
Progression of Carcinoid Heart Disease in the Modern Management Era
Journal of the American Heart Association·2021· 7 citedOpen Access
Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a <i>Post Hoc</i> Analysis of the PRODIGE-GERCOR IDEA-France Trial
Clinical Cancer Research·2021· 94 citedOpen Access
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
European Journal of Cancer·2020· 17 cited
Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study
European Journal of Cancer·2019· 3 cited
P4653A natural history of carcinoid heart disease in the modern management era
European Heart Journal·2019
Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
Annals of Oncology·2019· 65 citedOpen Access
<i>BRAF</i> mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases
British journal of surgery·2019· 41 cited
A natural history of carcinoid heart disease in the modern management era
Archives of Cardiovascular Diseases Supplements·2019
Intégration de l’élicitation d’experts dans une méthode de sélection de variables en Bayésien par la méthode de power prior–Application au cancer du colon
Revue d Épidémiologie et de Santé Publique·2019
page 1 of 5Next →

Frequent Co-authors

Julien Taı̈eb(23), Philippe Rougier(21), Jean‐Baptiste Bachet(13), Thierry Lecomte(11), David Tougeron(10), Romain Coriat(10), Olivier Bouché(10), Simon Pernot(9), Denis Smith(9), Emmanuel Mitry(9), Aziz Zaanan(9), Michel Ducreux(8), Jean-Nicolas Vaillant(8), Jean‐François Seitz(8), Bruno Landi(8), Roger Faroux(7), Emmanuel Mitry(7), Olivier Dubreuil(7), Jaafar Bennouna(7), Rosine Guimbaud(7)